multidoseinitial series,then 1 doseat 2-6monthsFractureRiskAssessmentTool50y.o.≥6.5%40y.o.Gailmodel2 doses,2-6monthsapart≥ 126mg/dLdyslipidemialungcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorstamoxifen≥ 200mg/dLq5y≥20%HepatitisBherpeszoster≥ 100mg/dLwomenage 55-64 y.o.insufficientevidenceforscreeningq1-2ymammogrambased on lifeexpectancy /health statusbreastcanceroverweight/ obesity≥5.7%raloxifenedepression60y.o.q2yanxiety40-70 y.o.,ASCVD ≥10%, lowbleeding risk< 60y.o.65y.o.diabetesstatin52y.o.pneumococcal40-59 y.o.,ASCVD ≥10%, lowbleeding risk3%PREVENTequationhypertensionTimedup andgo testcolorectalcancerhormonetherapy≤q2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factordementia≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factortobaccouse75y.o.q1yq1ymammogramaspirincervicalcancercommunity-dwelling,postmenopausalwomenHepatitisCq15yaromataseinhibitors40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsHIVq3y1 dose; 2doses (2-6monthsapart) ifimmunocompovariancancerTyrer-Cuzickmodelcardiovasculardiseasemultidoseinitial series,then 1 doseat 2-6monthsFractureRiskAssessmentTool50y.o.≥6.5%40y.o.Gailmodel2 doses,2-6monthsapart≥ 126mg/dLdyslipidemialungcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorstamoxifen≥ 200mg/dLq5y≥20%HepatitisBherpeszoster≥ 100mg/dLwomenage 55-64 y.o.insufficientevidenceforscreeningq1-2ymammogrambased on lifeexpectancy /health statusbreastcanceroverweight/ obesity≥5.7%raloxifenedepression60y.o.q2yanxiety40-70 y.o.,ASCVD ≥10%, lowbleeding risk< 60y.o.65y.o.diabetesstatin52y.o.pneumococcal40-59 y.o.,ASCVD ≥10%, lowbleeding risk3%PREVENTequationhypertensionTimedup andgo testcolorectalcancerhormonetherapy≤q2y40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factordementia≥ 140mg/dL40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factortobaccouse75y.o.q1yq1ymammogramaspirincervicalcancercommunity-dwelling,postmenopausalwomenHepatitisCq15yaromataseinhibitors40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsHIVq3y1 dose; 2doses (2-6monthsapart) ifimmunocompovariancancerTyrer-Cuzickmodelcardiovasculardisease

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. multidose initial series, then 1 dose at 2-6 months
  2. Fracture Risk Assessment Tool
  3. 50 y.o.
  4. ≥ 6.5%
  5. 40 y.o.
  6. Gail model
  7. 2 doses, 2-6 months apart
  8. ≥ 126 mg/dL
  9. dyslipidemia
  10. lung cancer
  11. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  12. tamoxifen
  13. ≥ 200 mg/dL
  14. q5y
  15. ≥ 20%
  16. Hepatitis B
  17. herpes zoster
  18. ≥ 100 mg/dL
  19. women age 55-64 y.o.
  20. insufficient evidence for screening
  21. q1-2y mammogram based on life expectancy / health status
  22. breast cancer
  23. overweight / obesity
  24. ≥ 5.7%
  25. raloxifene
  26. depression
  27. 60 y.o.
  28. q2y
  29. anxiety
  30. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  31. < 60 y.o.
  32. 65 y.o.
  33. diabetes
  34. statin
  35. 52 y.o.
  36. pneumococcal
  37. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  38. 3%
  39. PREVENT equation
  40. hypertension
  41. Timed up and go test
  42. colorectal cancer
  43. hormone therapy
  44. ≤ q2y
  45. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  46. dementia
  47. ≥ 140 mg/dL
  48. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  49. tobacco use
  50. 75 y.o.
  51. q1y
  52. q1y mammogram
  53. aspirin
  54. cervical cancer
  55. community-dwelling, postmenopausal women
  56. Hepatitis C
  57. q15y
  58. aromatase inhibitors
  59. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  60. HIV
  61. q3y
  62. 1 dose; 2 doses (2-6 months apart) if immunocomp
  63. ovarian cancer
  64. Tyrer-Cuzick model
  65. cardiovascular disease